metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population
versus interferon alpha
	Ipilimumab (10 mg/kg)
	E1609 (ipi10), 2020 J Clin Oncol 2020; 38:567-575 NCT01274338	RCT	mML - NA - all population	ipilimumab 10 mg/kg	HDI high dose of interferon alpha	melanoma of cutaneous or unknown primary origin (AJCC 7th edition stage IIIB, IIIC, or IV [M1a or M1b]) who were rendered disease free surgically. No priorsystemic adjuvant therapy was permitted.	511 / 636	high	inconclusive	inconclusive 12 % decrease in deaths (OS) (PE) inconclusive 16 % decrease in RFS/DFS (PE)
versus placebo
	Ipilimumab (10 mg/kg)
	EORTC 18071, 2015 N. Engl. J. Med. 2016; 375:1845-1855 Lancet Oncol. 2017; 18:393-403 Eur. J. Cancer 2019; 119:1-10 Lancet Oncol. 2015; 16:522-30 NCT00636168	RCT	mML - NA - all population	ipilimumab	placebo	patients with completely resected high-risk stage III melanoma who had not received previous systemic therapy for melanoma	475 / 476	low	conclusif	demonstrated 28 % decrease in deaths (OS) (PE) demonstrated 25 % decrease in RFS/DFS (PE) demonstrated 24 % decrease in MFS (PE) suggested 27 % decrease in deaths (OS) (extension) more...
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population
versus ipilimumab alone
	Ipilimumab (10 mg/kg)
	Ascierto (ipi 10 vs 3 mg/kg), 2017 Lancet Oncol. 2017; 18:611-622 NCT01515189	RCT	mML - L2 - all population	ipilimumab 10 mg	Ipilimumab 3 mg	Patients with untreated or previously treated unresectable stage III or IV melanoma, without previous treatment with BRAF inhibitors or immune checkpoint inhibitors,	365 / 362	low	conclusif	demonstrated 16 % decrease in deaths (OS) (PE)